Autifony Announces Results from Completed CLARITY-1, Phase IIa Trial of AUT00063 in Age-related Hearing Loss

9 August 2016

London – UK – 09 August 2016 – Autifony Therapeutics Limited, which is pioneering the development of novel pharmaceutical treatments for hearing disorders and other serious disorders of the central nervous system, today released the results of its CLARITY-1 clinical trial of AUT00063 conducted in subjects with age-related hearing loss.